Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 4/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | HRH1 | P35367 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
| ▸ | KDM1A | O60341 | 2/20 | 0.35 |
| ▸ | MAOB | P27338 | 2/20 | 0.35 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.34 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.34 |
| ▸ | CNR1 | P21554 | 1/20 | 0.34 |
| ▸ | HTR1B | P28222 | 1/20 | 0.34 |
| ▸ | MTOR | P42345 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9709892 | 0.95 | KDM1A (0.40) | EPHX2KCNH2KDM1AMAOBMTNR1A | |
| SCHEMBL9827438 | 0.91 | ALDH1A1 (0.40) | — | |
| SCHEMBL9710008 | 0.89 | CYP19A1 (0.41) | EPHX2KDM1AMAOBMTNR1AMTNR1B | |
| SCHEMBL9771158 | 0.88 | MTNR1A (0.41) | EPHX2MTNR1AMTNR1BCNR1 | |
| SCHEMBL9827663 | 0.87 | ALDH1A1 (0.40) | EPHX2 | |
| SCHEMBL9771022 | 0.85 | SIGMAR1 (0.43) | KCNH2SIGMAR1MTOR | |
| SCHEMBL9867117 | 0.85 | L3MBTL1 (0.43) | EPHX2SIGMAR1CNR1 | |
| SCHEMBL9828096 | 0.84 | NPY1R (0.38) | — | |
| SCHEMBL9119383 | 0.83 | CYP19A1 (0.43) | HTR2AHRH1SIGMAR1HTR1B | |
| SCHEMBL9866251 | 0.82 | SIGMAR1 (0.42) | EPHX2SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0302896-B1 | N-(W-SUBSTITUTED ALKYL)-N'-[(IMIDAZOLE-4-YL)ALKYL]GUANIDINE | CEDONA PHARMACEUTICALS B.V. (NL) | 1991-08-14 | — | — | EP | claimed |
| US-5021431-A | H-1 antagonist, h-2 agonist for treating hypertension, cardiac disease or arterial occlusion | HEUMANN PHARMA GMBH & CO. (DE) | 1991-06-04 | — | — | US | claimed |
| EP-0302896-B1 | N-(W-SUBSTITUTED ALKYL)-N'-[(IMIDAZOLE-4-YL)ALKYL]GUANIDINE | CEDONA PHARMACEUTICALS B.V. (NL) | 1991-08-14 | — | — | EP | disclosed |
| US-5021431-A | H-1 antagonist, h-2 agonist for treating hypertension, cardiac disease or arterial occlusion | HEUMANN PHARMA GMBH & CO. (DE) | 1991-06-04 | — | — | US | disclosed |
| EP-0199845-B1 | IMIDAZOLYLALKYLGUANIDIN DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | HEUMANN PHARMA GMBH & CO (DE) | 1990-08-01 | — | — | EP | disclosed |
| EP-0199845-A1 | Imidazolylalkylguanidin derivatives, process for their preparation and pharmaceutical compositions containing them | HEUMANN PHARMA GMBH & CO (DE) | 1986-11-05 | — | — | EP | disclosed |